Stocktoria
Ultragenyx Pharmaceutical Inc. RARE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-01-31
Ultragenyx Pharmaceutical Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $673.0M | $560.0M | $434.0M | $363.3M | $351.4M |
| R&D expense | $750.0M | $698.0M | $648.0M | $705.8M | $497.2M |
| SG&A expense | $349.0M | $321.0M | $310.0M | $278.1M | $220.0M |
| Operating income | -$535.0M | -$536.0M | -$569.0M | -$648.9M | -$381.7M |
| Income tax | $4.0M | $2.0M | -$2.0M | $5.7M | $1.0M |
| Net income | -$575.0M | -$569.0M | -$607.0M | -$707.4M | -$454.0M |
| EPS (diluted) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 |
| Operating cash flow | -$466.0M | -$414.0M | -$475.0M | -$380.5M | -$338.7M |
| Free cash flow | -$472.0M | -$421.0M | -$519.0M | -$496.6M | -$411.8M |
| Cash & equivalents | $421.0M | $174.0M | $214.0M | $132.9M | $307.6M |
| Inventory | $52.0M | $45.0M | $34.0M | $26.8M | $16.2M |
| Total assets | $1.5B | $1.5B | $1.5B | $1.5B | $1.5B |
| Total liabilities | $1.6B | $1.2B | $1.2B | $1.2B | $599.8M |
| Shareholders' equity | -$80.0M | $255.0M | $275.0M | $352.0M | $922.6M |
Source: SEC EDGAR filings · CIK 0001515673 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.